Breaking New Ground -- Forest Laboratories, Inc. Expands to Canadian Market
Forest Laboratories Canada Inc. focused on bringing new treatment options to
TORONTO, Jan. 22, 2013 /CNW/ - Forest Laboratories, Inc. (NYSE: FRX) - an
international pharmaceutical company - today announced its entry into the
Canadian market through its wholly owned subsidiary Forest Laboratories Canada
Inc. This development is in furtherance of Forest's plans to expand in global
"We are excited about our venture in the Canadian marketplace," said Greg
Engel, General Manager, Forest Laboratories Canada Inc. "We intend to
introduce products that offer new treatment options that can address unmet
medical needs and help improve patients' medical conditions. The company's
goal is to bring important therapies to those Canadians who need them in
compliance with Rx&D's Code of Ethical Practices. In the near-term, Forest
Laboratories Canada Inc. is focused on bringing a number of therapeutic
options to market in the areas of cardiology, respiratory medicine,
gastroenterology, and mental health."
The Canadian head office is based in Toronto, Ontario, with a sales team that
will reach from coast-to-coast.
About Forest Laboratories Canada Inc. & Forest Laboratories, Inc.
Forest Laboratories Canada Inc., the Canadian operation of Forest
Laboratories, Inc. (NYSE: FRX), is dedicated to delivering innovative
healthcare solutions across multiple therapeutic areas to patients with unmet
medical needs. Forest Laboratories Canada Inc. is headquartered in Toronto,
Ontario. To learn more, visit www.frx.ca.
Forest Laboratories, Inc.'s longstanding global partnerships and track record
developing and marketing pharmaceutical products in the United States have
yielded its well-established central nervous system and cardiovascular
franchises and innovations in anti-infective, respiratory, gastrointestinal
and pain management medicine. Forest Laboratories, Inc.'s pipeline, the most
robust in its history, includes product candidates in all stages of
development across a wide range of therapeutic areas. Forest Laboratories,
Inc. is headquartered in New York, NY. To learn more, visit www.FRX.com.
Except for the historical information contained herein, this release may
contain forward-looking statements within the meaning of United States
securities laws. These statements may involve a number of risks and
uncertainties, including the difficulty of predicting regulatory approvals,
the acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories, Inc.'s Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and any subsequent U.S. Securities and Exchange Commission filings.
Neither Forest Laboratories Canada Inc. nor Forest Laboratories, Inc. assumes
any obligation to update any forward-looking statements contained in this
release to reflect new information or future events or developments.
Frank J. Murdolo VP Investor Relations Forest Laboratories, Inc. 212-224-6714
Jacqueline Zonneville NATIONAL Public Relations 416-848-1398
SOURCE: Forest Laboratories Canada Inc.
To view this news release in HTML formatting, please use the following URL:
CO: Forest Laboratories Canada Inc.
-0- Jan/22/2013 14:00 GMT
Press spacebar to pause and continue. Press esc to stop.